BRAIN Biotech AG (XTER:BNN) Cash And Cash Equivalents : €10.17 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Cash And Cash Equivalents?

BRAIN Biotech AG's quarterly cash and cash equivalents declined from Sep. 2023 (€5.35 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€10.17 Mil).

BRAIN Biotech AG's annual cash and cash equivalents declined from Sep. 2021 (€24.55 Mil) to Sep. 2022 (€8.44 Mil) and declined from Sep. 2022 (€8.44 Mil) to Sep. 2023 (€5.35 Mil).

BRAIN Biotech AG Cash And Cash Equivalents Historical Data

The historical data trend for BRAIN Biotech AG's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Cash And Cash Equivalents Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Cash And Cash Equivalents

Get a 7-Day Free Trial

15.16

18.94

24.55

8.44

5.35

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial															9.16	-	5.35	-	10.17

BRAIN Biotech AG Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BRAIN Biotech AG (XTER:BNN) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BRAIN Biotech AG Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines